Shares of Celsus Therapeutics PLC (NASDAQ:AKTX) have earned an average broker rating score of 5.00 (Strong Sell) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell recommendation.
Brokerages have set a 1-year consensus target price of $5.00 for the company, according to Zacks. Zacks has also given Celsus Therapeutics PLC an industry rank of 92 out of 265 based on the ratings given to its competitors.
Several research analysts have recently commented on AKTX shares. Canaccord Genuity set a $33.00 target price on Celsus Therapeutics PLC and gave the stock a “buy” rating in a research report on Monday, August 15th. Chardan Capital started coverage on Celsus Therapeutics PLC in a research report on Monday, July 11th. They issued a “sell” rating and a $5.00 target price for the company.
A hedge fund recently bought a new stake in Celsus Therapeutics PLC stock. NEA Management Company LLC acquired a new position in shares of Celsus Therapeutics PLC (NASDAQ:AKTX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 452,167 shares of the biopharmaceutical company’s stock, valued at approximately $6,100,000. Celsus Therapeutics PLC makes up 0.3% of NEA Management Company LLC’s holdings, making the stock its 27th largest position. NEA Management Company LLC owned about 3.84% of Celsus Therapeutics PLC as of its most recent SEC filing. 35.70% of the stock is owned by institutional investors and hedge funds.
Celsus Therapeutics PLC (NASDAQ:AKTX) opened at 8.51 on Thursday. The stock has a 50 day moving average price of $9.34 and a 200-day moving average price of $12.93. Celsus Therapeutics PLC has a 12 month low of $7.63 and a 12 month high of $23.00. The stock’s market cap is $100.21 million.
About Celsus Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsus Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsus Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.